{"ok":true,"trend":{"id":618368,"platform":"news","region":"global","key":"new leqselvi® (deuruxolitinib) two-year data in severe alopecia areata showed sustained efficacy and safety at eadv congress 2026","title":"New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026","url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOSXpNRnY3OWcyUFRqMERPUzJhSTRJOUxpQ21Rc2xKNDBmNkpsTXRWUXdyOXR3YWdQYkpDMXpIa3pTT3NNcEpVNW1fSE5sWktvTWFFWm1LU1haaXhTYndfa1F2NVRQZ19HeEN3UVRzc19JT2hKOXpnWWdja1JxS3p4Zm5SdUtycE9qUnVUbE1MbFBxVVZkUkV5Rmg1eGJWRHRhcVg0TDNsQ281TEtWcmtFb2tFb0EyUkNMYkE4TzdYejExYmJGUW15VVdZYlp1cWRyRTFVdU8zRHhZbjNUVTd0b3cwNjF6M2toU0FIYW9uWm9CMXozRGphYWdXYnZkWi1PVEo0bjZFQXgzeVBYYWo4?oc=5","first_seen":"2026-10-01T14:24:53.837959Z","last_seen":"2026-10-01T15:46:17.964574Z","last_rank":23,"peak_rank":20,"last_volume":null,"peak_volume":0,"seen_count":2,"score":29.64,"category_hint":"us_politics","section":"world","category":"us_politics","summary":"Sun Pharmaceutical announced two-year clinical data for LEQSELVI (deuruxolitinib) in severe alopecia areata, presented at the EADV Congress 2026. The results showed sustained efficacy and a consistent safety profile in patients over the extended treatment period. The findings reinforce the drug's long-term value for people with severe hair loss, though discussion so far appears limited to the announcement itself.","why":"unclear","tone":"positive","entities":["Sun Pharmaceutical","LEQSELVI","deuruxolitinib","EADV Congress 2026","alopecia areata"],"summarized_at":"2026-10-01T14:25:38.242663Z","meta":{"via":"scan","lang":"en","term":"congress","source":"prnewswire.com","published":"Thu, 01 Oct 2026 12:30:00 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Two-Year Data for Alopecia Drug LEQSELVI Shows Sustained Efficacy","section_name":"World","category_name":"US Politics","timeline":[{"captured_at":"2026-10-01T14:24:53.837959Z","rank":20,"volume":null},{"captured_at":"2026-10-01T15:46:17.964574Z","rank":23,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOSXpNRnY3OWcyUFRqMERPUzJhSTRJOUxpQ21Rc2xKNDBmNkpsTXRWUXdyOXR3YWdQYkpDMXpIa3pTT3NNcEpVNW1fSE5sWktvTWFFWm1LU1haaXhTYndfa1F2NVRQZ19HeEN3UVRzc19JT2hKOXpnWWdja1JxS3p4Zm5SdUtycE9qUnVUbE1MbFBxVVZkUkV5Rmg1eGJWRHRhcVg0TDNsQ281TEtWcmtFb2tFb0EyUkNMYkE4TzdYejExYmJGUW15VVdZYlp1cWRyRTFVdU8zRHhZbjNUVTd0b3cwNjF6M2toU0FIYW9uWm9CMXozRGphYWdXYnZkWi1PVEo0bjZFQXgzeVBYYWo4?oc=5","author":"PR Newswire","title":"New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026","snippet":null,"posted_at":"2026-10-01T12:30:00Z","likes":null}],"elsewhere":[],"window":"7d"}}